Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$41.90 USD
-0.09 (-0.21%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $41.89 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.90 USD
-0.09 (-0.21%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $41.89 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
Zacks News
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
by Zacks Equity Research
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Cerevel Therapeutics Holdings, Inc. (CERE) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Cerevel Therapeutics (CERE) Might Surprise This Earnings Season
by Zacks Equity Research
Cerevel Therapeutics (CERE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
by Zacks Equity Research
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
New Analyst Coverage Puts Spotlight on These 4 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.
Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I
by Zacks Equity Research
Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.
Company News for Jun 30, 2021
by Zacks Equity Research
Companies in the news are: EPAC, CERE, PLBY, MRNA